The addition of durvalumab to standard first-line chemotherapy extended survival among patients with advanced biliary tract cancer, according to topline data released by the agent’s manufacturer.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
